Samsung's $1. 8 Billion Bet on Peptide Therapeutics: A Strategic Gamble in a Crowded Market Samsung Biologics' recent all cash bid of $1.
8 billion for Switzerland's PolyPeptide Group has sent shockwaves through the biopharmaceutical industry.
At first glance, this deal appears to be a shrewd move by Samsung Biologics to diversify its portfolio and tap into the lucrative market for peptide based therapeutics.